ATE540053T1 - Fermentationsprozess zur produktion von diphtherie-toxin - Google Patents

Fermentationsprozess zur produktion von diphtherie-toxin

Info

Publication number
ATE540053T1
ATE540053T1 AT09176267T AT09176267T ATE540053T1 AT E540053 T1 ATE540053 T1 AT E540053T1 AT 09176267 T AT09176267 T AT 09176267T AT 09176267 T AT09176267 T AT 09176267T AT E540053 T1 ATE540053 T1 AT E540053T1
Authority
AT
Austria
Prior art keywords
fermentation process
diphtheria toxin
producing diphtheria
producing
culture
Prior art date
Application number
AT09176267T
Other languages
English (en)
Inventor
Phillippe Marc Helene Dehottay
Sandrine Dessoy
Olivier Marc Serge Ghislain Laloux
Marc Roger Fernand Orval
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of ATE540053T1 publication Critical patent/ATE540053T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT09176267T 2005-03-23 2006-03-21 Fermentationsprozess zur produktion von diphtherie-toxin ATE540053T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0505996.9A GB0505996D0 (en) 2005-03-23 2005-03-23 Fermentation process

Publications (1)

Publication Number Publication Date
ATE540053T1 true ATE540053T1 (de) 2012-01-15

Family

ID=34531759

Family Applications (2)

Application Number Title Priority Date Filing Date
AT09176267T ATE540053T1 (de) 2005-03-23 2006-03-21 Fermentationsprozess zur produktion von diphtherie-toxin
AT06723804T ATE449788T1 (de) 2005-03-23 2006-03-21 Fermentationsverfahren zur herstellung von diphterietoxin

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT06723804T ATE449788T1 (de) 2005-03-23 2006-03-21 Fermentationsverfahren zur herstellung von diphterietoxin

Country Status (14)

Country Link
US (2) US20080193475A1 (de)
EP (2) EP2174950B1 (de)
JP (1) JP4917087B2 (de)
KR (1) KR101341121B1 (de)
CN (1) CN101180313B (de)
AT (2) ATE540053T1 (de)
AU (1) AU2006226542B2 (de)
BR (1) BRPI0609692C1 (de)
CA (1) CA2602143C (de)
DE (1) DE602006010676D1 (de)
ES (2) ES2335133T3 (de)
GB (1) GB0505996D0 (de)
RU (1) RU2394914C2 (de)
WO (1) WO2006100108A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102159540B (zh) * 2008-07-21 2015-08-12 布赖汉姆妇女医院 与合成的β-1,6葡糖胺寡糖相关的方法和组合物
IT1398927B1 (it) 2009-06-25 2013-03-28 Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi Espressione batterica di un gene artificiale per la produzione di crm197 e derivati.
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
EP2865390B1 (de) 2012-06-20 2019-08-21 The University of Tokyo Mukosales immunitätsstimulierendes mittel und orale pharmazeutische zusammensetzung zur behandlung von hpv-infektionen
CN103627758B (zh) * 2012-08-28 2018-04-27 天士力医药集团股份有限公司 一种crm197蛋白的生产方法
US20140193451A1 (en) * 2012-10-17 2014-07-10 Glaxosmithkline Biologicals Sa Immunogenic composition
BE1022174B1 (fr) 2013-03-15 2016-02-24 Glaxosmithkline Biologicals S.A. Vaccin
CN110366428B (zh) 2016-12-30 2024-05-17 Vaxcyte公司 具有非天然氨基酸的多肽-抗原缀合物
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
US11219680B2 (en) 2017-02-24 2022-01-11 Merck Sharp & Dohme Corp. Polysaccharide-protein conjugates utilizing diphtheria toxin fragment B as a carrier
SMT202200356T1 (it) * 2017-04-22 2022-11-18 Biological E Ltd Un metodo migliorato per produzione ad alto livello di crm
US12397014B2 (en) 2019-02-05 2025-08-26 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
EP3699263A1 (de) 2019-02-22 2020-08-26 GlaxoSmithKline Biologicals S.A. Gärungsprozess
CN110452838B (zh) * 2019-07-18 2020-12-29 艾美卫信生物药业（浙江）有限公司 一种crm197菌种培养基、配制方法及发酵培养方法
WO2021176409A1 (en) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Preservative combination for vaccine composition
CN115058474B (zh) * 2022-05-23 2025-02-14 艾美坚持生物制药有限公司 一种提高crm197蛋白产量的发酵培养方法
CN114806973B (zh) * 2022-06-08 2024-02-23 艾美坚持生物制药有限公司 一种提高crm197蛋白产量的生长因子及其制备方法和应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
EP0027888B1 (de) 1979-09-21 1986-04-16 Hitachi, Ltd. Halbleiterschalter
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
CH660375A5 (it) 1983-02-08 1987-04-15 Sclavo Spa Procedimento per la produzione di proteine correlate alla tossina difterica.
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
WO1990006951A1 (en) 1988-12-16 1990-06-28 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Pneumolysin mutants and pneumococcal vaccines made therefrom
WO1991013090A1 (en) 1990-03-02 1991-09-05 Diane Williams Improved chimeric toxins
CA2087160A1 (en) 1990-07-16 1992-01-17 P. Frederick Sparling Antigenic iron repressible proteins from n. meningitidis related to the hemolysin family of toxins
US5912336A (en) 1990-08-23 1999-06-15 University Of North Carolina At Chapel Hill Isolated nucleic acid molecules encoding transferrin binding proteins from Neisseria gonorrhoeae and Neisseria meningitidis
ES2329979T3 (es) 1990-08-23 2009-12-03 The University Of North Carolina At Chapel Hill Proteinas de union de transferencia de neisseria gonorrhoeae y neisseria meningitis. su uso como vacuna.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
FR2682041B1 (fr) 1991-10-03 1994-01-14 Pasteur Merieux Serums Vaccins Vaccin contre les infections a neisseria meningitidis.
ES2204900T3 (es) 1992-02-11 2004-05-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Estructura inmuinogena de doble vector.
CA2135052A1 (en) 1992-05-06 1993-11-11 R. John Collier Diphtheria toxin receptor-binding region
SG48365A1 (en) 1992-05-23 1998-04-17 Smithkline Beecham Biolog Combined vaccines comprising hepatitis b surface antigen and other antigens
PT652758E (pt) * 1992-06-18 2000-04-28 Harvard College Vacinas de toxina da difteria
FR2692592B1 (fr) 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
DE69323264D1 (de) * 1992-10-27 1999-03-11 American Cyanamid Co Pädiatrische Kombinationsvakzine mit verbesserter Immunogenizität jeder Vakzine komponente
ATE280235T1 (de) 1993-03-05 2004-11-15 Wyeth Corp Plasmid zur herstellung von crm-protein und diphtherie-toxin
JP3429313B2 (ja) 1993-05-18 2003-07-22 オハイオ・ステイト・リサーチ・ファウンデーション 中耳炎ワクチン
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US5917017A (en) * 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6265567B1 (en) 1995-04-07 2001-07-24 University Of North Carolina At Chapel Hill Isolated FrpB nucleic acid molecule
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
EA199800046A1 (ru) 1995-06-07 1998-06-25 Байокем Вэксинс Инк. Полипептид, последовательность днк, вакцинная композиция (варианты), антитело или его фрагмент, вакцина, применения указанных полипептида, последовательности днк и антитела или его фрагмента
PL184872B1 (pl) 1995-06-23 2003-01-31 Smithkline Beecham Biolog Kombinowana szczepionkaĆ zestaw do przygotowania kombinowanej szczepionkiĆ sposób wytwarzania kombinowanej szczepionki i jej zastosowanie
ES2262177T3 (es) 1996-05-01 2006-11-16 The Rockefeller University Proteinas de union a colina para vacunas frente a neumococos.
FR2751000B1 (fr) 1996-07-12 1998-10-30 Inst Nat Sante Rech Med Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
JP4469026B2 (ja) 1996-10-31 2010-05-26 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅの抗原およびワクチン
EP0998557A2 (de) 1997-07-21 2000-05-10 North American Vaccine, Inc. Modifizierte immunogene pneumolysin, deren zusammensetzungen und deren verwendungen als impfung
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
DE69942176D1 (de) 1998-04-07 2010-05-06 Medimmune Llc Choline-bindende proteine derivate aus pneumokoken als impfstoff
EP2261338A3 (de) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Antigene und Zusammensetzungen gegen Neisseria meningitidis
WO2000023595A1 (en) 1998-10-22 2000-04-27 The University Of Montana Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof
GB9904582D0 (en) 1999-02-26 1999-04-21 Nycomed Imaging As Process
KR100401423B1 (ko) 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법
WO2006042542A2 (en) * 2004-10-19 2006-04-27 Statens Serum Institut Production of tetanus, diphtheria, and pertussis toxins and toxoids using fermentation media containing no components of animal or soy origin
US9473463B2 (en) 2014-07-29 2016-10-18 Combined Conditional Access Development & Support, LLC Control word and associated entitlement control message caching and reuse

Also Published As

Publication number Publication date
EP2174950B1 (de) 2012-01-04
KR101341121B1 (ko) 2013-12-12
WO2006100108A1 (en) 2006-09-28
EP1861420A1 (de) 2007-12-05
KR20070116132A (ko) 2007-12-06
BRPI0609692B8 (pt) 2020-01-21
AU2006226542A1 (en) 2006-09-28
RU2007135122A (ru) 2009-04-27
BRPI0609692C1 (pt) 2021-05-25
JP2008533980A (ja) 2008-08-28
CN101180313A (zh) 2008-05-14
ES2335133T3 (es) 2010-03-22
CA2602143C (en) 2016-08-09
GB0505996D0 (en) 2005-04-27
ES2378193T3 (es) 2012-04-09
DE602006010676D1 (de) 2010-01-07
RU2394914C2 (ru) 2010-07-20
CN101180313B (zh) 2012-10-03
BRPI0609692A2 (pt) 2010-04-20
EP1861420B1 (de) 2009-11-25
ATE449788T1 (de) 2009-12-15
AU2006226542B2 (en) 2012-02-09
JP4917087B2 (ja) 2012-04-18
EP2174950A1 (de) 2010-04-14
US20140242635A1 (en) 2014-08-28
US20080193475A1 (en) 2008-08-14
CA2602143A1 (en) 2006-09-28
BRPI0609692B1 (pt) 2019-02-12

Similar Documents

Publication Publication Date Title
ATE540053T1 (de) Fermentationsprozess zur produktion von diphtherie-toxin
ATE542886T1 (de) Verfahren zur herstellung von l-arginin mit corynebacterium glutamicum
PL1664318T3 (pl) Mikroorganizm wytwarzający L-aminokwas i sposób wytwarzania L-aminokwasu
González-Fernández et al. Impact of temperature and photoperiod on anaerobic biodegradability of microalgae grown in urban wastewater
MX2010009984A (es) Selección de organismos capaces de fermentar sustratos mixtos.
ATE374531T1 (de) Verstaerkte produktion von lipiden enthaltend mehrfachungesaettigte fettsaeuren durch hochdichte kulturen von eukariotischen mikroben in gaervorrichtungen
ATE439427T1 (de) Neue kaumagenbakterienvarianten sowie verfahren zur herstellung von bernsteinsäure unter verwendung davon
MX2007005132A (es) Medios libres de proteina animal para cultivo de celulas.
Michielsen et al. Spatially structured microbial consortia and their role in food fermentations
DE60238863D1 (de) Vorrichtung und verfahren zur fermentation in hohen zelldichten
EP2848680A3 (de) Hefestämme und Verfahren zur Verwendung davon
DE60226243D1 (de) Peptidsynthasegen, peptidsynthase und verfahren zur herstellung eines dipeptids
ATE551418T1 (de) Verfahren und vorrichtung zur anaeroben fermentation von organischem material
ATE515562T1 (de) Mikroorganismen des genus corynebakteriums mit erhöhter l-lysin-produktionsfähigkeit und verfahren zur herstellung von l-lysin damit
ATE552345T1 (de) Verfahren zur herstellung von fermentationsprodukten
ATE524540T1 (de) Verfahren zur herstellung von l-aminosäuren unter verwendung von stämmen der familie enterobacteriaceae
ATE386134T1 (de) Verfahren zur herstellung von glutathion
ATE312937T1 (de) Verfahren zur herstellung von l-glutaminsäure
ATE254183T1 (de) Verfahren zur herstellung von exopolysaccharide
ATE216725T1 (de) Verfahren zur herstellung von l-isoleucin durch fermentation und l-homoserine als einzige stickstoffquelle
ATE542887T1 (de) Neuartiger milchsäurebakterienstrang, fermentiertes nahrungsmittel/getränk und verfahren zur herstellung eines fermentierten nahrungsmittels/getränks
JP6925169B2 (ja) 有機酸産出促進剤、有機酸の製造方法及び培養方法
RU2322496C2 (ru) Использование фосфокетолазы для продукции полезных метаболитов
WO2002064811A3 (fr) Procede pour produire des proteines recombinantes, marquees par au moins un isotope
Bastías et al. Effect of the energy and carbon source limitations and ferric inhibition on metabolic parameters of Leptospirillum ferrooxidans growing in chemostat